Combination therapies with allele‐specific covalent KRAS p.G12C inhibitors and anti‐EGFR targeted therapy have recently shown promising results in advanced colorectal cancer patients with KRAS c.34G>T (p.G12C) mutation.13, 14, 35, 36. Here, KRAS is linked to colorectal cancer.